Category: Correspondence

What means “non-war?”

There’s a serious error in David Leonhardt’s December 31 op-ed bidding farewell to 2017: “I expect that future historians will look back on it as one of the darker non-war years in the country’s history…” How do Leonhardt and the Times’s editors and fact-checkers and style book define “non-war?”  US military personnel are fighting seven wars in concert with US contractors, and maintaining bases in more than a hundred foreign countries. We, the people, spent countless billions in 2017 on the machinery of war. (Countless because we’re not allowed to know how much is in the “black budget.”)  Those of us who follow the news are reminded every night that “we” are conducting military campaigns in Afghanistan, Syria, Somalia, Yemen… When, by Leonhardt’s reckoning, was the last “war” year in our country’s history? Fred Gardner, Alameda CA (print subscriber reachable at...

Read More

Add Trippet Kudos

From Los Angeles defense specialist Bruce Margolin re Pebbles Trippet Gets Her Due in the Anderson Valley Advertiser: I am pleased to see that Pebbles is getting the recognition she deserves. Her and her Doc, Tod Mikuriya, went to bat for all of us and WON an important decision in the law that continues to have impact. I recall her contacting me at the time of the case was going on and wanted my help. With much regret I was caught up with my busy practice and couldn’t commit to her case at that time . I want to...

Read More

Her neurologist ‘was not against the idea’

Frank Lucido, MD, was thanked in the letters column of the San Francisco Chronicle December 28 (and so was the paper itself). Thank you from the bottom of my heart for your extensive research into medical cannabis. You have saved my sanity and given my life back to me. I have had a mild seizure disorder for 30-plus years, and have struggled with the side effects of various medications prescribed to control it. Honestly, the meds had more impact on my life than the disease: muddled thinking, balance problems, not caring if I woke up in the morning and...

Read More

Epidiolex getting priority review from FDA

Press release from GW Pharmaceuticals December 28, 2017: GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its recently submitted New Drug Application (NDA) for  Epidiolex® (cannabidiol or CBD), an investigational treatment for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome, two rare and difficult to treat conditions of childhood-onset epilepsy. The PDUFA (Prescription Drug User Fee Act) goal date for completion of the FDA review of the Epidiolex NDA...

Read More